the company’s pipeline and scientific leadership in small molecule medicines, biotherapeutics and vaccines. He is a member of the Pfizer Executive Leadership Team and co-chairs the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Dr. Dolsten leads the WRD group at Pfizer, which is responsible for all research at Pfizer, including development of all compounds through proof of concept, and provides safety, regulatory and clinical operation support to the entire R&D pipeline. Dr. Dolsten also has worldwide responsibility for Pfizer’s groups in safety, regulatory and development operations, and external R&D innovation in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development.

Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research. Before joining Wyeth, he served as Executive Vice President at Boehringer Ingelheim. His earlier career as a pharmaceutical research leader included positions with AstraZeneca, Pharmacia and Upjohn. Dr. Dolsten earned his PhD in tumor immunology and MD from Lund University in Sweden. He studied virology and cell biology at the Weizmann Institute in Israel, and he has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

Dr. Dolsten is a fellow of the New York Academy of Medicine, a governor of the New York Academy of Sciences and a member of the Board of Trustees of the New York Hall of Science. A member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA), Dr. Dolsten also serves on the PhRMA Foundation Board of Directors, and he is a member of the Government University Industry Research Roundtable (GUIRR). Dr. Dolsten is a named inventor on several patents. He has also published approximately 150 articles in international journals, with contributions in areas such as molecular cell biology, immunology and oncology.

Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), Director on the board of Imugene, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS), where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center, both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany, and further in surgery, molecular pathology and tumor immunology at Memorial Sloan Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.

and orphan infectious diseases. Prior to joining Ridgeback, Ms. Holman worked at U.S.-based ZBI Equities, a multi-billion dollar public-equity investment fund and its parent company, Ziff Brothers Investments. Between 1999 and 2014, she held various positions, including healthcare sector head and director of research at ZBI Equities and Principal at Ziff Brothers Investments. Wendy graduated from the University of Pennsylvania’s Wharton School and serves on the Board of Overseers for the Penn Libraries. She is the campaign chair for the University of Pennsylvania’s new Biotech Commons.

at Pontifax, an Israeli venture capital firm that invests in biopharmaceutical companies and medical devices. In this role, Mr. Rowbottom was responsible for expanding U.S. activities, including advising portfolio companies, identifying new investments and building relationships with investors and strategic partners. Before joining Pontifax, he was the head of capital markets for the Americas at KKR & Co. Prior to KKR, Mr. Rowbottom served in capital markets roles for Goldman Sachs, Barclays Capital and Citigroup. 

Mr. Rowbottom’s focus on early-stage healthcare companies stems from his personal experience as a melanoma patient who was treated in early clinical trials of checkpoint inhibitors. He is also influenced by a family member’s diagnosis with Ullrich congenital muscular dystrophy. He serves on the boards of the Melanoma Research Alliance and Cure CMD. Through these roles, Mr. Rowbottom collaborates closely with leading oncology researchers. He is a patient advocate and focuses on solutions to fund innovative basic research and clinical trials.

Mr. Rowbottom is also a founding investor and business adviser for Rgenix, a senior adviser for Trout, a Trustee of the Elisabeth Morrow School and a Trustee of Project Renewal. He holds a B.S. in finance from SUNY at Albany and an MBA from Columbia University.

Biotechnologies GmbH, helping to grow the company from a startup to an established biotech. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapeutics with clinical utility. Mr. Singh has played a leading role in raising over $200 million of venture capital funding over several financing rounds.

Since 2015, Mr. Singh has served as President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston to develop next-generation Adoptive Cell Therapies (ACT). He contributed significantly to raising the necessary funding, including a $20 million CPRIT grant by the State of Texas.

Mr. Singh is the inventor on numerous patents and patent applications. He has also co-authored approximately 30 publications in prestigious peer-reviewed journals, including Nature Medicine, Nature Biotechnology, Lancet Oncology and Journal of Experimental Medicine, Brain and Blood. A scholar of Prof. Hans-Georg Rammensee, Mr. Singh completed his academic studies by gaining a PhD in immunology at the University of Tuebingen in Germany.

Mr. van den Broek has extensive industry experience, including director roles on the boards of biotechnology companies where he advises companies of various sizes at diverse stages of development. He currently serves on the boards of Celldex Therapeutics, Inc., Response Genetics, Inc., CogState Limited and Special Diversified Opportunities, Inc. Previously, Mr. van den Broek served on the board of Pharmacyclics, L.L.C. prior to the company’s acquisition by AbbVie for $21 billion.

Prior to HSMR Advisors, he was a Partner of Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to working for Cooper Hill Partners, Mr. van den Broek had a 10-year career as a biotechnology analyst at Oppenheimer & Co., Merrill Lynch and Hambrecht & Quist. He graduated from Harvard University, and he holds the Chartered Financial Analyst designation.

Prior to that, Dr. Holman worked for the Merrill Lynch large pharmaceuticals equity research analyst. Dr. Holman earned his MD from New York University and his B.A. in Economics from Yale University.

Ridgeback Capital was founded in 2006, and it is focused on healthcare investments. Ridgeback invests in private and public companies dedicated to the development of life-saving and life-changing therapies. Healthcare advances take many years to materialize, and Dr. Holman believes that patient capital is vital for new technologies and companies to thrive.